Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 18Lymphoma, Large B-Cell, Diffuse 16Leukemia, Myeloid, Acute 16Hodgkin Disease 16Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lung Neoplasms 12Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Lymphoma, B-Cell 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 6Recurrence 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4Congenital Abnormalities 4Waldenstrom Macroglobulinemia 3Plasmablastic Lymphoma 3Ovarian Neoplasms 3Lymphoma, Primary Effusion 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Immunoblastic Lymphadenopathy 3

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic NUT Carcinoma × Etoposide × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡